POLYMERASE CHAIN-REACTION EVIDENCE FOR HUMAN IMMUNODEFICIENCY VIRUS-1 NEUTRALIZATION BY PASSIVE-IMMUNIZATION IN PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX

被引:61
作者
KARPAS, A
HEWLETT, IK
HILL, F
GRAY, J
BYRON, N
GILGEN, D
BALLY, V
OATES, JK
GAZZARD, B
EPSTEIN, JE
机构
[1] US FDA,CTR BIOL EVALUAT & RES,DIV BLOOD & BLOOD PROD,RETROVIROL LAB,BETHESDA,MD 20892
[2] ADDENBROOKE HOSP,PUBL HLTH LAB SERV,CAMBRIDGE CB2 2QH,ENGLAND
[3] ST STEPHENS & WESTMINSTER HOSP,LONDON SW1P 2AP,ENGLAND
关键词
immunotherapy;
D O I
10.1073/pnas.87.19.7613
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We tried to assess the long-term safety and potential efficacy of passive immunization in AIDS-related-complex (ARC) and AIDS patients. We also wanted to establish whether hyperimmune plasma from healthy human immunodeficiency virus 1 (HIV-1)-infected individuals clears the cell-free virus from circulation. Using the polymerase chain reaction (PCR), we were able to provide conclusive evidence that hyperimmune plasma is effective and maintains long-term neutralization of viremia. Using the cell test, we found that in most patients the total antibody level was maintained; in one of the ARC patients, it actually increased 8-fold and has remained at that level for nearly 2 years. The CD4+ cell count decreased in the AIDS patients but was stable in the ARC patient. Clinically, there was an initial improvement in all patients, but five of six of the advanced/terminal AIDS patients had died by month 17. Our studies suggest that passive immunization may be safe in ARC and AIDS patients. It reduces HIV-1 viremia to levels undetectable even by PCR. To advanced/terminal patients, the benefit is of limited duration, while to ARC patients it may be long-term. Therefore, passive immunization should start early in the disease.
引用
收藏
页码:7613 / 7617
页数:5
相关论文
共 25 条
  • [1] INCUBATION PERIOD OF AIDS IN SAN-FRANCISCO
    BACCHETTI, P
    MOSS, AR
    [J]. NATURE, 1989, 338 (6212) : 251 - 253
  • [2] HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 CHALLENGE OF CHIMPANZEES IMMUNIZED WITH RECOMBINANT ENVELOPE GLYCOPROTEIN GP120
    BERMAN, PW
    GROOPMAN, JE
    GREGORY, T
    CLAPHAM, PR
    WEISS, RA
    FERRIANI, R
    RIDDLE, L
    SHIMASAKI, C
    LUCAS, C
    LASKY, LA
    EICHBERG, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (14) : 5200 - 5204
  • [3] PLASMA VIREMIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTION
    COOMBS, RW
    COLLIER, AC
    ALLAIN, JP
    NIKORA, B
    LEUTHER, M
    GJERSET, GF
    COREY, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) : 1626 - 1631
  • [4] DOURNON E, 1988, LANCET, V2, P1297
  • [5] INFECTION AND REPLICATION OF HIV-1 IN PURIFIED PROGENITOR CELLS OF NORMAL HUMAN-BONE MARROW
    FOLKS, TM
    KESSLER, SW
    ORENSTEIN, JM
    JUSTEMENT, JS
    JAFFE, ES
    FAUCI, AS
    [J]. SCIENCE, 1988, 242 (4880) : 919 - 922
  • [6] HEWLETT IK, 1989, VACCINES 89, P167
  • [7] HUMAN-IMMUNODEFICIENCY-VIRUS NEUTRALIZING ANTIBODIES RECOGNIZE SEVERAL CONSERVED DOMAINS ON THE ENVELOPE GLYCOPROTEINS
    HO, DD
    SARNGADHARAN, MG
    HIRSCH, MS
    SCHOOLEY, RT
    ROTA, TR
    KENNEDY, RC
    CHANH, TC
    SATO, VL
    [J]. JOURNAL OF VIROLOGY, 1987, 61 (06) : 2024 - 2028
  • [8] QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS
    HO, DD
    MOUDGIL, T
    ALAM, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (24) : 1621 - 1625
  • [9] EFFECT OF IMMUNIZATION WITH A VACCINIA-HIV ENV RECOMBINANT ON HIV-INFECTION OF CHIMPANZEES
    HU, SL
    FULTZ, PN
    MCCLURE, HM
    EICHBERG, JW
    THOMAS, EK
    ZARLING, J
    SINGHAL, MC
    KOSOWSKI, SG
    SWENSON, RB
    ANDERSON, DC
    TODARO, G
    [J]. NATURE, 1987, 328 (6132) : 721 - 723
  • [10] JACKSON GG, 1988, LANCET, V2, P647